Limus

Quick links to important sections

Limus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Limus

Property Description
Active ingredient Quetiapine Fumarate
Form Oral Tablet (Immediate-Release and Extended-Release)
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
General purpose Stabilization of Central Nervous System Neurotransmission
Origin Synthetic Compound (Dibenzothiazepine Derivative)

What Type of Medicine is Limus (Quetiapine)?

Limus is a trade name for the synthetic compound Quetiapine Fumarate, which is a psychotropic agent classified as an atypical antipsychotic medication. This compound is a dibenzothiazepine derivative, a specific chemical class that defines its structure and targeted action within the central nervous system. Quetiapine is recognized as an essential medicine, confirming its established role in addressing key mental health needs globally.

It belongs to the group commonly referred to as second-generation antipsychotics (SGAs), a classification distinguishing it from older medications due to its broader spectrum of receptor modulation. The compound's distinct binding profile contributes to stabilizing thought processes and managing emotional shifts.

Composition, Form, and General Purpose of Quetiapine

The active component of this medication is Quetiapine Fumarate, a single-ingredient product administered exclusively via the oral route and formulated as a tablet. A notable differentiating feature is its availability in both an immediate-release (IR) form and an extended-release (XR) version; the XR formulation is designed with specialized excipients to release the active ingredient continuously over an extended period, which helps maintain stable levels in the blood.

The fundamental purpose of Quetiapine is achieved through neurotransmitter modulation, primarily functioning as an antagonist at critical brain receptors for chemical messengers like dopamine and serotonin. Quetiapine's mechanism involves complex interactions with these neurotransmitters to stabilize brain activity. This indicates the medication is specifically designed to help regulate and normalize communication pathways in the central nervous system, often utilized in clinical scenarios where the patient requires stabilization of erratic mood or disordered thinking.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Limus?

Possible Side Effects and Safety Information

The safety profile of Limus (Quetiapine Fumarate), an atypical antipsychotic, is formally classified by regulatory authorities based on the frequency and affected physiological system observed in clinical data.

Frequency and System-Organ Classifications

Adverse reactions are grouped into frequency tiers. Effects designated as Very Common (ge 1/10) include central nervous system effects such as somnolence and dizziness, along with dry mouth, headache, and certain metabolic changes like weight gain and altered lipid levels. Effects classified as Common (ge 1/100 to < 1/10) include orthostatic hypotension (dizziness upon standing), tachycardia, gastrointestinal issues like constipation, and neurological symptoms such as Extrapyramidal Symptoms (EPS). Common laboratory findings include elevations of liver enzymes and hormonal changes such as hyperprolactinemia.

Serious Adverse Reactions and Safety Constraints

Official labeling documents several serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS) and the potential for Tardive Dyskinesia, which involves involuntary movements. The drug is associated with changes in the metabolic profile, including a risk for hyperglycemia and new onset Diabetes Mellitus. The regulatory documents also warn about an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.

Population-Specific Safety Statements

Regulatory authorities state that Limus is contraindicated for use in elderly patients with dementia-related psychosis due to an increased risk of death and cerebrovascular adverse events. Safety information specifies that side effects like somnolence and orthostatic hypotension often arise during the initial dose-titration period and that the development of cataracts has been observed during long-term treatment.

Overdose and Emergency Response

The official prescribing information for Limus (Quetiapine Fumarate) documents specific clinical signs indicating overdose, primarily affecting the central nervous system (CNS) and the cardiovascular system (CVS).

System Documented Manifestations
CNS Profound drowsiness, delirium, seizures, and coma.
CVS Tachycardia (rapid heartbeat), hypotension (low blood pressure), and potentially life-threatening arrhythmias, including QT prolongation.

When Immediate Medical Help is Required

It is a regulatory mandate to seek immediate medical attention upon any suspected overdose. Emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened. The extended-release formulation may result in a delayed or prolonged duration of symptoms, requiring extended observation.

Official Management and Monitoring

The required management strategy is strictly symptomatic and supportive treatment, as no specific antidote is known. This includes ensuring adequate airway management and ventilation. Continuous monitoring is essential, particularly continuous electrocardiography (ECG), to watch for cardiotoxicity and arrhythmias in a healthcare facility.

Therapeutic Uses of Limus

Limus (Quetiapine Fumarate) is commonly used to help with symptoms associated with episodic or fluctuating manifestations and is applicable within clinical settings that involve acute or disruptive symptom patterns. This medication helps address symptom clusters that may become intense or disruptive.

It is commonly used to help with conditions involving both short-term symptomatic assistance and long-term management, including Schizophrenia, Bipolar Disorder (covering manic, depressive, and maintenance phases), and as an adjunctive treatment for Major Depressive Disorder (MDD) in adults. This application is relevant in contexts involving heightened systemic burden.

“It provides supportive relief when symptoms interfere with routine activities and assists with maintaining functional stability.”

In these contexts, the compound may be part of symptomatic management for recurrent manifestations, contributing to easing the overall symptom load and helping maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Disordered Thought and Extreme Mood Fluctuations

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Official regulatory documents establish clear restrictions regarding who can and cannot use Limus. The most critical restriction is a contraindication for any patient with a known, clinically significant hypersensitivity (allergic reaction) to the drug, its ingredients, or other rapamycin derivatives like sirolimus. Such patients must not take this medicine.

Age and Condition Restrictions

Population Group Regulatory Status
Hypersensitivity Contraindicated (Must not use)
Non-Kidney/Liver Transplant Use not established or not recommended
Severe Hepatic Impairment Not recommended (e.g., Child-Pugh Class C)
Pregnancy May cause fetal harm; not recommended
Lactation Not recommended (discontinue drug or nursing)

Eligibility for use is also determined by the specific context. For organ transplant prophylaxis, the drug is primarily approved for adult kidney and liver recipients; it is not established for use in other organ transplant types or in kidney transplant patients at high immunologic risk. In certain non-transplant indications, its use is established in pediatric patients aged one year and older. Use in patients with severe hepatic impairment is generally not recommended, while those with milder impairment may require monitoring and dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Limus (a class of drugs including everolimus and sirolimus) has a high potential for clinically significant drug interactions because it is primarily broken down by the enzyme CYP3A4 and is a substrate for the transporter P-glycoprotein (P-gp). Because Limus has a narrow therapeutic index, co-administration with other medicines that affect these systems requires careful management and therapeutic drug monitoring (TDM).

Key Interacting Agents and Categories

Interaction Category Interacting Agents (Examples) Resulting Effect on Limus Exposure
Potent Inhibitors of CYP3A4/P-gp Certain antifungals, macrolide antibiotics, calcium channel blockers Increased Limus concentrations (risk of toxicity)
Potent Inducers of CYP3A4/P-gp Certain anti-seizure medicines, Rifampin Decreased Limus concentrations (risk of therapeutic failure)
Calcineurin Inhibitors Cyclosporine, Tacrolimus Increased Limus concentrations (requires dose reduction)

Official regulatory information emphasizes that the combination of Limus with potent CYP3A4/P-gp inhibitors may be restricted, and if co-administration is necessary, Limus trough concentrations must be closely monitored, often requiring a dose reduction. Conversely, co-administration with potent inducers is generally restricted or requires a substantial dose increase and close TDM due to the risk of dangerously low Limus levels. The administration of Limus with Cyclosporine is associated with significantly increased Limus exposure, which necessitates specific timing requirements and dose adjustments as defined in the official prescribing information.

Mechanism of Action

The physiological actions of Limus are defined by its complex and concentration-dependent interactions with multiple receptors in the central nervous system (CNS), creating distinct mechanistic domains that collectively shape its profile.

Neurotransmitter System Modulation

The core action involves the transient antagonism of D2 dopamine receptors combined with high-affinity antagonism of 5-HT2 A serotonin receptors. This dual-system modulation, enhanced by the metabolite norquetiapine's action on norepinephrine signaling, is the mechanism used to modulate signaling flow in affected communication pathways within the CNS.

Mechanism of Central Nervous System Depression

Limus exhibits high affinity for the Histamine H1 receptor ( H1 R). This high-affinity antagonism rapidly suppresses the histamine-driven system responsible for regulating wakefulness, leading to the predictable physiological effect of profound central nervous system depression and sedation.

Autonomic Receptor Influence

The drug acts as an antagonist on alpha1 adrenergic receptors, found in both the CNS and the peripheral vascular system. This mechanism directly alters the body's control of blood vessel tone, resulting in a systemic physiological consequence of peripheral vasodilation.

Dosage and Administration Information

How to Use Limus (Quetiapine Fumarate)

The usage of Quetiapine Fumarate is defined by specific protocols governing administration route, dosing schedules, and physical handling for the Immediate-Release (IR) and Extended-Release (XR) tablet forms.

Administration Route and Timing

Limus is used for oral administration. The frequency of use depends on the formulation:

Dosage Form Frequency Pattern Timing in Relation to Meals
Immediate-Release (IR) Administered in a divided regimen, typically two to three times daily. May be taken with or without food.
Extended-Release (XR) Administered once daily. Should be taken without food or with a light meal.

Dosing Protocol and Special Handling

Therapy begins with a low initial dose followed by a titration—a gradual increase over several days—to reach the therapeutic maintenance dose. The maximum daily dose for most adult indications is generally 800 mg/day.

  • Tablet Handling: The Extended-Release tablet must be swallowed whole and is prohibited from being split, crushed, or chewed, as this action compromises the controlled release of the active ingredient.
  • Population Adjustments: A lower starting dose (e.g., 25 mg/day) and a slower titration rate are the standard protocol for older adults and patients with hepatic impairment. In case of a missed dose, the general procedural rule is to skip the forgotten dose if it is near the next scheduled time, and never take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Limus (Quetiapine Fumarate)


Evidence for Use in Schizophrenia

The clinical evaluation of Limus for schizophrenia was evaluated in numerous research protocols, predominantly Randomized Controlled Trials (RCTs). These short-term studies, typically lasting 3 to 6 weeks, were primarily conducted to compare the compound against an inactive substance (placebo) in populations experiencing heightened symptom activity. The trials used standardized measurement tools, such as the PANSS score, to track how symptoms evolved in the observed populations. Beyond acute stabilization, research has also explored the long-term patterns observed during follow-up, monitoring responses over defined time intervals to research whether a potential recurrence or relapse of symptoms was observed. Research describes patterns observed in patients who had previously responded to treatment.

Evidence for Use in Bipolar Disorder

The research base covers conditions characterized by fluctuating or episodic manifestations across three distinct study scenarios: acute mania, acute depression, and long-term recurrence prevention.

Study Focus: Acute Mania and Depression

For acute manic episodes, short-term RCTs were used in research exploring short-term symptom changes, primarily using the Young Mania Rating Scale (YMRS) score. Studies examined measurements when the compound was used alone (monotherapy) and when it was observed alongside established mood stabilizing medication (adjunctive therapy). For acute depressive episodes, research primarily focused on Limus as monotherapy in 8-week RCTs, monitoring changes in depressive symptoms using tools like the MADRS total score.

Study Focus: Maintenance and Recurrence Prevention

Research exploring the recurrence prevention study scenario involved long-term controlled studies following stabilized adults for up to two years. Research examined the time to recurrence of any mood event. Studies report how symptoms evolved in the observed populations over these extended durations, and research describes patterns related to maintaining stability by observing the time to recurrence of mood events.

Research Gaps and Remaining Uncertainties

Research highlights that long-term outcomes related to functional recovery are not fully established, and evidence is limited compared to short-term symptom measurements. Data for older adults, particularly those with comorbid conditions, remain insufficient for drawing broad conclusions. Comparative evidence directly assessing Limus against every other available treatment option across all indications is lacking.

Frequently Asked Questions (FAQ)

Common questions about Limus (FAQ)

Q: What is the main medical use of Limus?

Regulatory documents state that this medicine is approved for treating conditions such as schizophrenia and bipolar disorder. It is also approved for use as an add-on treatment for major depressive disorder in certain populations.

Q: Is Limus used for more than one approved condition?

Yes, official prescribing information confirms that it is approved for treating multiple conditions. These include schizophrenia and different episodes related to bipolar disorder, showing its function in stabilizing various thought and mood processes.

Q: Does Limus cure the condition or only help manage it?

According to official product information, this medicine functions to help manage symptoms. It is a tool for stabilizing communication pathways in the central nervous system, but it does not cure the underlying condition.

Q: Why is Limus sometimes called an immunosuppressant medicine?

The chemical name for this medicine is chemically distinct from drugs that suppress the immune system. The confusion likely stems from the 'limus' suffix, which is associated with a different class of medications (e.g., Sirolimus) that work on the immune system.

Q: Can Limus affect kidney function over time?

Dose adjustments are not typically needed for most kidney impairment according to official guidelines. However, regulatory information notes that serious kidney problems have been reported in the post-marketing setting.

Q: What signs indicate a person may be having a severe reaction to Limus?

Official safety warnings describe signs of a severe reaction, which include very high fever, muscle stiffness, increased sweating, or symptoms of a severe allergic reaction. Severe allergic symptoms include swelling of the face or throat and difficulty breathing.

Q: Does alcohol change the way Limus works in the body?

Official labeling describes that use with alcohol is associated with an increased risk of side effects. Alcohol can enhance the drug's effects, increasing the potential for excessive sleepiness, dizziness, and a sudden drop in blood pressure upon standing.

Q: Are there certain vitamins or supplements that should be avoided with Limus?

Certain supplements like St. John's wort and the food/drink grapefruit (or grapefruit juice) are listed in official documents as substances that may affect the concentration of the medication in the body. This interaction may raise the risk of side effects.

Q: Is there a difference between brand-name Limus and its generic versions?

Generic versions must demonstrate to regulatory authorities that they are bioequivalent to the brand-name product. This means the body absorbs and processes them in the same way. While generic products contain the same active ingredient, small differences may exist in inactive ingredients.

Q: What happens in general if a person accidentally takes too much Limus?

Accidentally taking too much may lead to symptoms of overdose. These effects can include excessive drowsiness, profound sedation, low blood pressure, confusion, and heart rhythm changes. Official regulatory documents list these as potential consequences.

Q: How quickly can a person expect to notice any effects from Limus?

The sedative effects of the medicine may begin within hours of taking a dose. Improvement in targeted symptoms may be noticed within one week of use, but the full therapeutic benefit often takes a few months to become apparent, according to clinical information.

Q: What common foods or drinks are known to interact with Limus?

Regulatory documents explicitly identify grapefruit and grapefruit juice as substances that interact. These foods and drinks are noted as being capable of increasing the drug's concentration in the blood, which raises the potential risk of side effects.

Q: Can I take Limus with over-the-counter pain medications?

Regulatory guidelines describe that patients should provide a healthcare provider with a list of all prescription and nonprescription medicines being used. This includes any over-the-counter pain medications, as some may affect how the body processes the drug.

Q: Is Limus commonly prescribed to older or elderly patients?

This medicine carries a regulatory warning stating that it is not approved for use in older adults with psychosis related to dementia. Official documents indicate that use in this group is associated with an increased risk of death.

Q: What are the general expectations for long-term health monitoring while taking Limus?

Official product information requires periodic monitoring for long-term use. This typically includes regular blood work checks for changes in blood sugar and cholesterol levels, as well as periodic eye examinations for cataracts.

Q: Does Limus weaken the body's overall ability to fight infections?

The regulatory label requires monitoring for a low white blood cell count, a condition called agranulocytosis, which is a rare but serious adverse effect. The presence of infection signs is generally noted as requiring prompt attention in regulatory materials.

Q: Does Limus have known interactions with common high blood pressure medicines?

Regulatory documents note that caution is associated with the use of this medicine alongside other drugs that affect blood pressure. Because the drug itself can cause orthostatic hypotension, combining it with certain blood pressure medicines may increase the risk of dizziness or fainting.

Q: Can my existing health issues be made worse by taking Limus?

Official warnings indicate that taking this medicine may worsen certain existing health issues. Patients with a history of heart conditions, seizures, or uncontrolled diabetes are noted as requiring special consideration and close monitoring.

How should Limus be stored and disposed of?

Storage and Disposal Requirements

Limus (quetiapine fumarate) tablets must be stored according to specific environmental and container rules to maintain their stability.

Storage Component Official Requirement
Temperature Store at 25 C (77 F); excursions permitted between 15 to 30 C (59 to 86 F).
Protection Keep in the original container and protect from moisture.
Child Safety Store securely out of the sight and reach of children.
Disposal Rule Do not dispose of via wastewater or household waste.

Disposal of unused or expired medication must align with all local, regional, and national regulations. Patients should consult a pharmacist or local waste disposal service for guidance on proper collection and disposal to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Limus found in:

A-Z Index: